Table 5 Effects of non-dose parameters on dermatitis grade
Grade 1 (n = 22) | Grade 2 (n = 53) | Grade 3 (n = 26) | Total | |
|---|---|---|---|---|
Neoadjuvant chemotherapy | ||||
(−) | 17 (28.3%) | 34 (56.7%) | 9 (15.0%) | 60 |
(+) | 5 (12.2%) | 19 (46.3%) | 17 (41.5%) | 41 |
Concurrent chemotherapy | ||||
Radiotherapy alone | 6 (26.1%) | 15 (65.2%) | 2 (8.7%) | 23 |
Platinum | 12 (22.6%) | 29 (54.7%) | 12 (22.6%) | 53 |
Cetuximab | 4 (16.0%) | 9 (36.0%) | 12 (48.0%) | 25 |
Treatment technique | ||||
IMRT-4X | 7 (15.2%) | 23 (50.0%) | 16 (34.8%) | 46 |
VMAT-6X | 15 (27.3%) | 30 (54.5%) | 10 (18.2%) | 55 |
Sex | ||||
Male | 16 (20.8%) | 37 (51.4%) | 22 (27.8%) | 75 |
Female | 6 (24.1%) | 16 (58.6%) | 4 (17.2%) | 26 |
Age (years) | ||||
< 67 | 10 (18.2%) | 32 (58.2%) | 13 (23.6%) | 55 |
≥ 67 | 12 (26.1%) | 21 (45.7%) | 13 (28.3%) | 46 |
BMI (kg/m2) | ||||
< 18.5 | 2 (8.0%) | 14 (56.0%) | 9 (36.0%) | 25 |
≥ 18.5 | 20 (26.3%) | 39 (51.3%) | 17 (22.4%) | 76 |
Diabetes | ||||
Yes | 3 (23.0%) | 7 (53.9%) | 3 (23.1%) | 13 |
No | 19 (22.0%) | 46 (52.3%) | 23 (26.1%) | 88 |
Hypertension | ||||
Yes | 7 (23.0%) | 18 (60.0%) | 5 (16.7%) | 30 |
No | 15 (21.0%) | 35 (49.3%) | 21 (29.6%) | 71 |
Any comorbidity | ||||
(Charlson Comorbidity Index> 1) | ||||
Yes | 1 (10.0%) | 5 (50.0%) | 4 (40.0%) | 10 |
No | 21 (23.0%) | 48 (52.8%) | 22 (24.2%) | 91 |
Smoking | ||||
Concurrent | 7 (17.0%) | 20 (48.8%) | 14 (34.1%) | 41 |
Ex | 7 (19.0%) | 21 (56.8%) | 9 (24.3%) | 37 |
Never | 8 (35.0%) | 12 (52.2%) | 3 (13.0%) | 23 |